A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs

​ Conditions: Tumor Patients

Interventions: Drug: Trilaciclib and Topoisomerase I inhibitor type ADC drugs

Sponsors: Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting Conditions: Tumor Patients
Interventions: Drug: Trilaciclib and Topoisomerase I inhibitor type ADC drugs
Sponsors: Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting